Emilyn’s research at CERI focuses on applying next-generation sequencing (NGS) technologies for precision medicine and genomic surveillance of TB and other bacteria. “I’m involved in efforts to improve the diagnosis and treatment of drug-resistant TB using genomics-informed algorithms, particularly through the GenPath Africa project, Precision Action for Rifampicin-Resistant TB (PARR-TB) sub-study,” says Emilyn – who also contribute to the consolidation of surveillance networks in Brazil, with interests in BRICs countries. “This type of research is critical because it helps public health systems respond more quickly and effectively to outbreaks and drug resistance, and ensures that innovation reaches vulnerable populations.”

CERI actively fosters an inclusive environment that values diverse perspectives, including those of women in science. “As a woman from Latin America working in Africa, I have felt welcomed and respected for my contributions. CERI provides not only the infrastructure but also the mentorship and collaborative spaces needed for women to thrive, whether you're leading a research project, mentoring students, or contributing to institutional development,” says Emilyn. “Personally, I’ve had opportunities to grow both scientifically and as a leader, and I deeply value the commitment to equity and empowerment I see across the institute.”

One of the proudest moments in Emilyn’s career was being part of the establishment of a genomic surveillance network for TB in the North and Northeast regions of Brazil, areas often neglected in scientific investments. “Seeing the impact of our work on shaping local health policy, training researchers or public health personnel, and empowering regional labs, was incredibly fulfilling,” she explains, adding that it reminded her that science is not only about discovery, but also about building bridges and ensuring that innovation serves everyone – especially the most vulnerable.